drawbacks associated with traditional agents, direct Factor Xa inhibitors (e.g. rivaroxaban, apixaban, and edoxaban) and direct thrombin inhibitors (e.g. dabigatran etexilate) have been developed and are undergoing late-stage clinical evaluation for the prevention and treatment of thromboembolic ...
Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of th... Direct oral anticoagulants (DOAs) – inhibitors of thrombin or factor-Xa – are expected to replace vitamin K antagonists in most of their ...
The peptide can be directed to any region of the protein kinase C isozyme, and in one embodiment, is directed to the V5 domain. The peptide can be ... Chen Leon,W Sarah,Macelan Derek 被引量: 0发表: 2007年 Axon regeneration with PKC inhibitors 18. cpPKC3109 (competitive +++ ++++ ...
Lovenox 100 mg/mL Concentrationcontains 10 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1000 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection. Lovenox 150 mg/mL Concentrationcontains 15 mg enoxapa...
Side chain modified 5-deazafolate and 5-deazatetrahydrofolate analogues as mammalian folylpolyglutamate synthetase and glycinamide ribonucleotide formyltransferase inhibitors: Synthesis and in vitro biological evaluation Journal of Medicinal Chemistry (1992) ...
Human Transfer factor,TF ELISA KitDetails Synthesis of specific mature microRNA (MIRNA) antisense inhibitorsDetails Human ester acylglycerol kinase DG (DGKZ) ELISA kitDetails Methyl sulphateCH4O4SDetails Nonylphenol monoethoxylate (TECH)Details Deoxyribonucleotide triphosphate (DNTPS) mixtureDetails ...
#1953296 c-met-inhibitors.com Worth #1953297 bartels-mikrotechnik.de Worth #1953298 c0meawaywithme.blogspot.c Worth #1953299 bartelsmedical.com Worth #1953300 c19recoveryawareness.com Worth #1953301 barter.co.th Worth #1953302 c2pu.blogspot.com Worth #1953303 barterblvd.s3.ca-central- Worth #1953...
Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic...